SCHEMBL4191982

SCHEMBL4191982

COc1ccc(CS(=O)(=O)C(C#N)=Cc2ccc(F)cc2F)cc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
POLB P06746 2/20 0.43
EGFR P00533 1/20 0.42
ERBB2 P04626 1/20 0.42
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
GAA P10253 1/20 0.39
TAS2R14 Q9NYV8 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4191978 1.00 LMNA (0.48) LMNAMEN1KMT2APOLBEGFR
SCHEMBL4191974 1.00 LMNA (0.48) LMNAMEN1KMT2APOLBEGFR
SCHEMBL4185235 0.89 KMT2A (0.45) LMNAMEN1KMT2APOLBEGFR
SCHEMBL4185371 0.89 SIRT2 (0.43) LMNAMEN1KMT2APOLBEGFR
SCHEMBL4185233 0.89 KMT2A (0.45) LMNAMEN1KMT2APOLBEGFR
SCHEMBL4185378 0.89 SIRT2 (0.43) LMNAMEN1KMT2APOLBEGFR
SCHEMBL4185381 0.89 SIRT2 (0.43) LMNAMEN1KMT2APOLBEGFR
SCHEMBL4185236 0.89 KMT2A (0.45) LMNAMEN1KMT2APOLBEGFR
SCHEMBL4182928 0.88 MEN1 (0.46) LMNAMEN1KMT2APOLBEGFR
SCHEMBL4182922 0.88 MEN1 (0.46) LMNAMEN1KMT2APOLBEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090191193-A1 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-07-30 US disclosed
EP-2046322-A2 ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2009-04-15 EP disclosed
WO-2008016682-A2 ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090191193-A1 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof ARSA, STS, SULT2A1 LMNA 4621/4885MEN1 2503/4885KMT2A 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.